A Randomized, Multi-center, Single Dose, Cross over Study Comparing the Pharmacokinetic of Bio-similar EPTACOG Alfa with NOVOSEVEN®, in Patients with Congenital Factor VII Deficiency
Phase of Trial: Phase III
Latest Information Update: 14 Feb 2019
At a glance
- Drugs Eptacog alfa (Primary)
- Indications Factor VII deficiency
- Focus Pharmacokinetics
- Sponsors AryoGen Pharmed
- 05 Feb 2019 Status changed from active, no longer recruiting to recruiting.
- 05 Feb 2019 Planned End Date changed from 1 Apr 2019 to 1 Dec 2019.
- 05 Feb 2019 Planned primary completion date changed from 1 Jul 2018 to 1 Jun 2019.